Interobserver agreement between emergency clinicians and nurses for Clinical Opiate Withdrawal Scale

Christian A. Tomaszewski MD MBA  |  Faith Quenzer DO  |  Bryan Corbett MD  |  Andrew Lafree MD  |  Daniel Lasoff MD  |  Jorge Romo PA-C  |  Leslie Mukau MD

Department of Emergency Medicine, University of California, San Diego and the El Centro Regional Medical Center, San Diego, California, USA

Correspondence Department of Emergency Medicine, University of California, San Diego and the El Centro Regional Medical Center, 9902 Rue Biarritz, San Diego, CA 92131, USA.
Email: leslie.mukau@gmail.com

Funding and support: By JACEP Open policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org).

Dr. Tomaszewski was supported by a grant from the Sierra Health Foundation. Medication for Addiction Treatment (MAT) Access Points - Prevention and Education in Communities of Color funding opportunity. Dr. Corbett has a grant from the Sierra Health Foundation Medication-Assisted Treatment Access Points Awards to enhance MAT access, recruitment, and retention by expanding the existing Buprenorphine MAT program in the Emergency Department. Drs. Mukau and Lasoff each have the California Public Health Institute (PHI) Bridge program and the Department of Health Care Service (DHCS) Behavioral Health Pilot Project grants that combine Medication for Addiction Treatment (MAT) in hospital emergency departments with support from a substance use counselor to help people get into ongoing substance use treatment.

Abstract

Objectives: The Clinical Opiate Withdrawal Scale (COWS) is a validated, commonly used tool to objectively quantify withdrawal symptoms, often in anticipation of treatment with buprenorphine. Our primary aim was to determine the agreement between emergency department (ED) nurses compared with emergency physicians in determining this score in ED patients who presented for opioid withdrawal treatment. Secondarily, we wanted to investigate the safety of buprenorphine induction in the ED setting.

Methods: Scoring for opioid withdrawal using the COWS was performed by ED clinicians and ED nurses independently on 120 patients. In addition to overall concordance, agreement (weighted kappa) was calculated between the 2 scores by various cutoffs: overall severity, COWS ≥ 5, and the 11 different individual measures. Patient documents also were reviewed for complications that could be possibly linked to buprenorphine induction.

Results: Our study sample of 120 subjects was 77% Hispanic and 78.3% male. The clinicians assigned a median interquartile range overall COWS score of 6 (2–12), which categorizes as mild withdrawal. Seventy-eight (65%) subjects met the criteria of withdrawal (≥ 5 COWS) and 69 (58%) received an induction dose of buprenorphine (range 2 mg–24 mg) during the ED visit. No adverse effects or worsening withdrawal were reported. The overall observed concordance, based on severity withdrawal categorization, for all clinician pairs, was 67.5% (81/120) (95% confidence interval [CI], 58.7–75.2%). The weighted kappa for that concordance was 0.55 (95% CI, 0.43–0.67), giving a moderate strength of agreement. When data are dichotomized by COWS score ≥ 5, concordance was 82.5% (99/120) (95% confidence interval [CI], 73.7–88.3%) and the weighted kappa was 0.65 (95% CI, 0.51–0.78), indicating substantial agreement. The breakdown by the 11 factors that constitute COWS showed only substantial agreement for pulse measurement.
Conclusion: The agreement between ED clinicians and nurses for the overall COWS scoring in patients presenting for opioid withdrawal treatment was substantial. COWS scoring by ED nurses may help expedite treatment with buprenorphine on presentation.

1 | INTRODUCTION

Opioid use disorder (OUD) is a significant public health crisis in the United States with drug overdose deaths increasing in 2019 after a slight decrease in 2018.1,2 The current increase in mortality is primarily driven by illicitly manufactured fentanyl.3 Randomized clinical trials have demonstrated the effectiveness of medication for addiction treatment (MAT).4-7 There is increasing evidence demonstrating the overall benefit of OUD opioid agonist treatment for OUD patients. Current research shows a reduction in mortality, especially in overdose deaths in patients given OUD opioid agonist therapy with methadone and buprenorphine;5-11 decreased illicit opioid use, and involvement with the criminal justice system;4,12,13 reduction in transmission of infectious diseases such as HIV and hepatitis C;14-15 and increased retention in OUD treatment6,12,17 as well as reduced health care costs.18-20

1.1 | Background

The emergency department is often a 24/7/365 focal point for patients suffering from complications of OUD. It is common for ED clinicians to encounter the same patient multiple times over any given time period. Therefore, the ED is a logical and appropriate place to start MAT. Major regulatory groups, including the Joint Commission21 and Substance Abuse and Mental Health Services Administration,22 have recommended improvements in the diagnosis and treatment of OUD. An accurate and rapid assessment of opioid withdrawal is important in the clinical management of opioid-dependent patients. There have been multiple tools used in the past to accurately identify and treat opiate withdrawal patients; however, these tools have not been well-validated.23 The Clinical Opioid Withdrawal Scale (COWS) is a commonly used 11-item validated tool to identify patients with possible opioid withdrawal.23,24 It provides a way for emergency clinicians to objectively assess opioid withdrawal.

1.2 | Importance

With the expanded use of buprenorphine and the potential for precipitating withdrawal, clinicians have developed algorithms for the initiation of buprenorphine in the ED. These algorithms include a minimum COWS score to appropriately initiate treatment in the ED or clinic while avoiding unnecessarily precipitating opioid withdrawal. ED nurses are usually the first line in engaging patients as they make initial contact with them. Based on the expeditious evaluation by ED nursing staff, there is potential to quickly score patients in triage and start treatment if needed, thereby avoiding escalation of symptoms or, even worse, elopement.

1.3 | Goals of this investigation

Currently, there is no study that has compared nursing to physician COWS scoring of patients with a potential opioid withdrawal syndrome. We analyzed our first-year data in our ED buprenorphine program to see how much concordance exists between the nurses and ED clinicians using COWS.

2 | METHODS

2.1 | Study design and setting

The study is a chart review involving a combination of both prospective and retrospective elements. Because this research study involved minimal risk and involved materials (data, documents, and records) that have been or were to be collected solely for non-research purposes, it qualified for both exempt criteria and expedited review of Title 45, Part 46 of the Code of Federal Regulations (CFR), specifically 45 CFR 46.101(b)(4) and 45 CFR 46.110 category 5.25 The research study was approved by meeting a waiver of consent by the Sierra Foundation Human Research Protections Program Institutional Review Board as well as the institution’s Human Study Ethics Board.

The study took place between July 1, 2019, and July 31, 2020 in a single-center community ED with an annual volume of 55,000 patients and located along the Southern California and Mexican international border region. This was a sample of all adults who were identified as having a COWS score assessed independently by both the patient’s nurse and ED clinician. The study period extended to a 13-month period rather than a traditional convenient 12 months to allow more patients for statistical validity.

ED clinicians as described in our study consist of ED physicians, physician assistants (PAs), or nurse practitioners (NPs). ED physicians assumed a supervisory role for PAs and NPs. Our program uses only registered nurses (RN) to provide direct care to patients and not licensed practical nurses (LPN). Both ED nurses and ED clinicians had similar training sessions on opiate withdrawal symptoms and
introducing them to scoring COWS based on physical examination. All patients were offered either buprenorphine induction, a prescription, or both. Within an hour of each other, but independently, both the nurse and clinician assigned to that patient independently assigned a COWS score. Because of separate charting within the electronic medical record (MedHost), the ED nurse and ED clinician were blinded to the score attribution by the other. Repeat COWS after buprenorphine induction was not mandated by the study protocol.

The hospital is located 12 miles north of the United States-Mexico border where 87.0% of the total population identify as LatinX/Hispanic. Additionally, the hospital site nursing staff also identify as LatinX/Hispanic and are bilingual. Most patients spoke English. Those patients who were Spanish speaking only communicated through certified Spanish interpreters who are also members of the ED staff.

For our study, we adopted the opioid withdrawal classification categories, which were initially introduced by Wesson and Ling in 2003 and based on the author’s clinical expertise.24 However, it was left to each individual clinician to decide at what withdrawal classification they would start buprenorphine induction.

The chart review methods and the data abstraction process were standardized. A database registry and tracking log of all patients seen in the ED for opiate use disorder was established and information entered retrospectively during the study period. One of the principal investigators certified in human subject research by the Collaborative Institutional Training Initiative and with experience in data abstraction and knowledgeable about the medical record was primarily responsible for data abstraction. For monitoring data validity and quality assurance, the study data at multiple intervals were cross-referenced with the original patient documents.

For each patient, baseline data including age, gender, ethnicity, and whether the patient received buprenorphine induction in the ED were collected. Data were also collected on the total dose of buprenorphine administered and the overall condition of the patient after induction. Post induction vital signs were noted including documentation of buprenorphine-precipitated withdrawal, respiratory depression, excessive sedation, or other unpleasant side effects such as feeling worse, itching, headache, nausea, or vomiting that could be attributed to buprenorphine. Additional clinical data collected at each COWS evaluation included date and time of assessment and clinician type (clinician versus nurse).

2.2 | Selection of participants

Patients were eligible for this study if they presented to the ED primarily for the treatment of opioid withdrawal. There were 142 patients identified as having a COWS performed independently by both the nurse and attending clinician. Eighteen observation pairs were removed for having more than 60 minutes between the nurse and clinician observations. An additional 2 pairs were removed for having incomplete subfactor information (pulse, sweating, restlessness, etc). In total, 120 pairs were included and analyzed.

2.3 | Measurements

We estimated the frequency of concordance between the overall COWS scores obtained by the 2 observers, clinician versus nurse. Their agreement was assessed categorically, first, based on overall degree of withdrawal: none 0–4; mild 5–12; moderate 13–24; moderate-severe 25–36; severe > 36. Second, the data were dichotomized by COWS score ≥ 5, which was the cutoff used for initiating buprenorphine in the ED. Finally, each COWS score was deconstructed into 11 categorical indices that contributed to the overall COWS score to examine agreement between clinician and nurse pairs.

2.4 | Statistical analysis

Simple concordance between clinician and scoring was calculated, along with 95% confidence intervals (CIs), and compared with a Bland-Altman plot. For time differences and overall scoring, due to nonnormally distributed data, we calculated medians with interquartile range (IQR) 1–3 range. To measure interobserver agreement, a weighted kappa statistic was used to measure concordance beyond chance. An agreement was considered perfect if kappa ≥ 0.8, substantial if 0.61 to 0.8, moderate 0.41 to 0.6, fair 0.21 to 0.4, and slight if below 0.2.26 Sample size calculation was based on a priori assumption that raters would classify 50% of subjects as positive (COWS scores ≥ 5) with an alpha of 0.05 and power of 0.80.27 Based on that calculation, we required a minimum of 96 subjects.

3 | RESULTS

3.1 | Characteristics of study subjects

We collected data on 120 subjects, 94 (78.3%) of whom were male with an average age of 38 years (range 19–70). Ninety-two (77%) of the 120 subjects identified primarily as Hispanic or Latino, 22 (18%) White/Non-Hispanic, 3 (2.5%) African American, and 3 (2.5%) Other. The median (IQR) time interval between nurse and clinician COWS assessment was 15 (6–30) minutes. Buprenorphine dosing for
induction was done during the index ED visit for 68 (57%) of the patients (Table 1). No adverse effects or worsening withdrawal was reported.

The median (IQR) overall COWS score, based on clinician scoring was a mild 6 (2–12), ranging from 0 (none) to 31 (moderate-severe), median based on nurse scoring, mild 5 (2–8.3) with range 0 (none)–27 (moderate-severe). Breakdown by category of withdrawal severity (based on clinician categorization), revealed that all patients with moderate to moderately severe withdrawal received buprenorphine (Table 2).

### 3.2 Main results

The Bland-Altman plot (Figure 1) shows that agreement generally good at lower mean overall COWS scores increasingly diverges at higher scores, that is, patients with worse withdrawal.

The overall observed concordance, based on severity withdrawal categorization, for all clinician pairs, was 67.5% (81/120) (95% CI, 58.7–75.2%). The weighted kappa for that concordance was 0.55 (95% CI, 0.43–0.66), giving a moderate strength of agreement. When data were dichotomized by COWS score ≥ 5, concordance was 82.5% (99/120) (95% CI, 74.7%–88.3%) and the weighted kappa was 0.65 (95% CI, 0.51–0.78), indicating substantial agreement. Further analysis by the 11 factors measured in calculating the COWS score, showed only substantial strength of agreement for pulse measurement; all other measures showed the highest agreement for observed (clinician-rated) measures of pulse and pupil size with less agreement among the rest of the measures, especially the subjective (patient-rated) items.

Repeat COWS scores were not a study protocol. However, a few clinicians and nurses documented repeat scores post buprenorphine induction and discharge. Although these scores were similar for the 2 study groups, the numbers were insufficient for statistical analysis.

### 3.3 Limitations

Brief training sessions with the nurses as well as clinicians in COWS scoring were performed before the study. Nursing staff who undergoes simulation and debriefing on opioid withdrawal cases had significant improvement in scoring outcome reliability but no change in confidence in correct scoring. Timing of assessment could have influenced our results, because nurses usually were the first to perform the COWS, followed by the clinicians. In addition to the sequence effect, the time gap, although minimal, could have decreased the agreement seen in this study. There is always the possibility that the clinicians could have previewed the nurse’s COWS score rather than performing an indirect COWS score independently through direct observation on the same patient. However, this was unlikely given the compartmentalization of the electronic record. In this chart review, data abstraction was not blinded to the purpose of the study and there is always a possibility that errors of intrarater reliability could arise by the possibility of contamination by knowledge of previous data coding because the same abstractor recorded the same set of variables.

The patient population was largely Hispanic (77%) and male (78.8%). This could raise questions about how generalizable this is to other patient populations, and whether language, culture, or bias affected patient’s COWS scores. Finally, obviously, there is no way possible to have a true gold standard for the COWS in this study because of the subjective nature of portions of the test.

### 4 DISCUSSION

OUD is currently a critical public health crisis. Although there are 3 Food and Drug Administration (FDA)-approved drugs that can be used for effective MAT, there are many obstacles standing in the gap. These roadblocks include lack of linkage to treatment facilities, federal restrictions limiting the availability of healthcare clinicians that can prescribe MAT, getting buy-in from ED clinicians that MAT is an appropriate use of the ED, and alleviating and overcoming their understandable fear of buprenorphine induced precipitated opiate withdrawal. COWS is the most used tool for assessing the severity of opioid withdrawal in the ED and is very simple to administer.

Recently, several treatment pathways have been employed for OUD, a chronic disease that can and should be treated. These therapeutic modalities usually involve opioid maintenance treatment,
**FIGURE 1** Bland-Altman plot showing comparison of Clinical Opioid Withdrawal Scale (COWS) scores between MD and registered nurse (RN) (mean of differences ± 95% limits of agreement)

**TABLE 3** Observed concordance along with weighted kappas for agreements by individual contributor to COWS

| Individual measurements       | Observed concordance | Weighted kappa | 95% CI LL | 95% CI UL | Strength of agreement |
|------------------------------|----------------------|----------------|-----------|-----------|-----------------------|
| Heart rate                   | 84.1%                | 0.78           | 0.68      | 0.88      | Substantial           |
| Sweating                     | 65.8%                | 0.45           | 0.31      | 0.59      | Moderate              |
| Restlessness                 | 64.2%                | 0.50           | 0.28      | 0.56      | Moderate              |
| Pupil size                   | 70.0%                | 0.18           | 0          | 0.38      | Fair                  |
| Bone/joint aches             | 60.0%                | 0.42           | 0.29      | 0.54      | Moderate              |
| Runny nose/tears             | 70.8%                | 0.33           | 0.15      | 0.51      | Fair                  |
| Gastrointestinal upset       | 65.0%                | 0.48           | 0.35      | 0.61      | Moderate              |
| Tremor                       | 65.0%                | 0.32           | 0.15      | 0.49      | Fair                  |
| Yawning                      | 81.7%                | 0.29           | 0.10      | 0.48      | Fair                  |
| Anxiety/irritability         | 58.3%                | 0.46           | 0.35      | 0.58      | Moderate              |
| Gooseflesh                   | 83.3%                | 0.44           | 0.21      | 0.66      | Moderate              |

Abbreviations: CI, confidence interval; COWS, Clinical Opiate Withdrawal Scale; LL, lower limit; UL, upper limit.

Detoxification (detox)\textsuperscript{29,30} and MAT (formerly known as medication-assisted treatment)\textsuperscript{31,32} MAT is an evidence-based treatment for OUD that combines behavioral therapy and FDA-approved medications including methadone, naltrexone, and buprenorphine. Opioid agonists like methadone and partial agonists like buprenorphine, substances that fully bind to and stimulate opioid receptors, are frequently used for both maintenance and detox purposes.\textsuperscript{33} There is evidence suggesting that medication-assisted treatment is more effective than opioid maintenance treatment and detox.\textsuperscript{34} In a recent comparative effectiveness research study of patients with OUD that compared 6 different treatment pathways, only treatment with buprenorphine or methadone was associated with reduced risk of overdose and serious
Effective opioid withdrawal management requires early identification and assessment of withdrawal symptoms. The main method of assessing and quantifying opioid withdrawal intensity has quintessentially involved withdrawal scales of some form with at least 18 different opioid withdrawal scales used within the last 80 years. Such scales tend to employ a combination of patients’ self-reports (symptoms), observable behaviors (signs), and/or measured physiological parameters. The scores for the 11-item COWS, the current most popular opioid withdrawal scale, range from 0 to 47 with specific ranges for the level of severity. Scores from 5 to 12 are considered mild, scores from 13 to 24 are considered moderate, scores from 25 to 26 are considered moderately severe, and scores more than 36 are considered severe withdrawal.

Although it has been recognized in clinical practice that there may be substantial interrater variability with COWS there is also a lack of consensus regarding the appropriate diagnostic thresholds to start ED buprenorphine induction. Different clinicians have adopted different levels of initial COWS levels on arrival to start buprenorphine induction. With the increasing availability of MAT in the controlled setting a target score of 5–12 is increasingly adopted. Even then a few clinicians are still comfortable to base their inductions purely on patient history and clinical assessment of presumed opioid withdrawal without a calculated and quantifiable scale.

The primary aim of our study was to determine if there was significant agreement between ED nurses compared to emergency physicians in determining this score in ED patients who presented for opioid withdrawal treatment. This study showed relatively good agreement between nurses and clinicians using COWS in patients presenting to the ED either in opioid withdrawal or in seeking help with opioid withdrawal. The best agreement was observed in using the treatment cutoff of ≥5.

To our knowledge, there are no prior clinical studies of interrater agreement between ED clinicians and nurses. Although the concordance was good in our study, it was not excellent. There are possible explanations for this. The COWS consists of observed (clinician-rated) as well as subjective (patient-rated) components of opiate withdrawal signs and symptoms. The COWS items can be identified as 6 objective items (resting heart rate, tremor, yawning, pupil size, gooseflesh skin, and runny nose or tearing), 1 subjective item (anxiety or irritability), and 4 items that have both objective and subject components (gastrointestinal upset, sweating, restlessness, and bone or joint aches). The subjective components can be interpreted and rated differently by different observers leading to interobserver variability. In our study, this was the first time both groups were calculating COWS scores. It would be the expectation that with practice and experience in time there would be a further boost to the agreement between the 2 groups. The clinical implications for patient care would be that any ED instituting a COWS protocol should have a concurrent audit initially.

The underlying premise behind clinical guidelines for therapeutic intervention in opiate withdrawal is that buprenorphine induction should occur in a patient who is physically dependent on opioids and is in mild to moderate withdrawal or waiting for that patient to be in moderate to severe opioid withdrawal. Different protocols suggest dosing at different COWS scores for buprenorphine induction for patients in mild to moderate withdrawal (COWS 5–24) in order to avoid precipitated withdrawal. In our study the best agreement was in using the treatment cutoff of ≥5 on COWS. At this level, we did not experience any precipitated withdrawal. Looking at this cutoff is important because it has the most implications for treatment. This is the level at which the first dose of buprenorphine is offered in realtime as opposed to discharge with a prescription, which we offered to all patients who accepted MAT.

Many clinicians still shy away from initiating buprenorphine induction in patients with mild withdrawal symptoms because of a fear of precipitated withdrawal. As evidenced in our study, buprenorphine precipitated withdrawal, although very real, may not be as common as clinicians think. However, it has recently been shown that about 1 in 20 patients treated for a non-fatal opioid overdose in an ED died within 1 year of their visit, many within 2 days following the visit. Two-thirds of these deaths were directly attributed to subsequent opioid-related overdoses. Immediate buprenorphine induction for many more patients with substance use disorder in the ED during the index visit and continued treatment after would save lives by reducing opioid-related deaths.

Based on prior studies, we expected that the ED nurses and emergency physicians to have an adequate amount of agreement using the COWS. Nurses, with brief training, can identify a COWS score to make appropriate changes in treatment plans of patients suffering from opioid withdrawal. Although our program does not use LPNs, we believe that even they too could be trained to score for COWS. Clinicians did tend to score patients higher for withdrawal, which may be a function of the time gap between nursing and physician scoring because in most practices nurses are at the bedside earlier than clinicians. An alternative explanation could be differences in the assessment approach. We expected the best agreement would be for pulse rate, one of the most objective measurements. Surprisingly, some of the more subjective measures, such as the presence of aches, restlessness, or anxiety, scored better than more objective measures, such as pupil size and tremor.

Although the patient population was largely Hispanic (77%) and male (78.8%), we believe that language, gender, culture, or implicit bias did not affect patient’s COWS scores. We feel that our findings could be generalizable to other patient populations.

In conclusion, we found that there is an adequate amount of agreement between nurses and emergency clinicians using the COWS. Future studies should be aimed at allowing expanded use of COWS for ED nurses in triaging opioid withdrawal patients, which can expedite proper identification and treatment of ED patients with buprenorphine.

**AUTHOR CONTRIBUTIONS**

CAT conceived the original study concept. CAT and LM refined the study design and obtained research funding. LM was responsible for the quality and accuracy of the data acquisition and handling. CAT and
FQ ran the statistical analysis of the data. Christian A. Tomaszewski-CAT drafted the manuscript, and all authors contributed substantially to its data analysis and revision. CAT and LM take responsibility for the paper as a whole.

All authors attest to meeting the 4 ICMJE.org authorship criteria: (1) Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND (2) Drafting the work or revising it critically for important intellectual content; AND (3) Final approval of the version to be published; AND (4) Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

CONFLICTS OF INTEREST
None.

REFERENCES
1. Hedegaard H, Miniño AM, Warner M. Drug overdose deaths in the United States, 1999–2018. NCHS data brief, no. 356. Hyattsville, MD: US Department of Health and Human Services, CDC, National Center for Health Statistics; 2020. https://www.cdc.gov/nchs/products/ databriefs/db356.htm
2. Wilson N, Kariisa M, Seth P, Smith H 4th, Davis NL. Drug and opioid-involved overdose deaths—United States, 2017-2018. MMWR Morb Mortal Wkly Rep. 2020;69:290-297. https://doi.org/10.15585/mmwr. mm6911a4.
3. O’Donnell J, Gladden RM, Mattson CL, et al. Vital signs: characteristics of drug overdose deaths involving opioids and stimulants: 24 states and the district of Columbia, January-June 2019. MMWR Morb Mortal Wkly Rep. 2020;69(35):1189-1197. https://doi.org/10.15585/mmwr.mm6935a1.
4. Mattick RP, Breen C, Kimber J, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;(2):CD002207. https://doi.org/10.1002/14651858.CD002207.pub4.
5. Kruipitsky E, Nunes EV, Ling W, et al. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicenter randomized trial. Lancet. 2011;377(9776):1506-1513.
6. Mattick RP, Breen C, Kimber J, et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;2009(3):1-19.
7. Lee JD, Friedmann PD, Kinlock TW, et al. Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. N Engl J of Med. 2016;374(13):1232-1242.
8. Degenhardt L, Bucello C, Mathers B, et al. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction. 2011;106(1):32-51.
9. Ma J, Bao YP, Wang RJ, et al. Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. Mol Psychiatry. 2019;24(12):1868-1883.
10. Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.
11. Krawczyk N, Eisenberg M, Schneider KE, et al. Predictors of overdose death among high-risk emergency department patients with substance-related encounters: a data linkage cohort study. Ann Emerg Med. 2020;75:1-12.
12. Sees KL, Delucchi KL, Masson C, et al. Methadone maintenance versus 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA. 2000;283(10):1303-1310.
13. Nielsen S, Larance B, Degenhardt L, et al. Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Database Syst Rev. 2016;2016(5):1-61.
14. Edelman EJ, Chantarat T, Caffrey S, et al. The impact of buprenorphine/naltrexone treatment on HIV risk behavior among HIV-infected, opioid-dependent patients. Drug Alcohol Depend. 2014;139:79-85.
15. Sullivan LE, Moore BA, Chawarski MC, et al. Buprenorphine/naltrexone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. J Subst Abuse Treat. 2008;35(1):87-92.
16. Gowling L, Farrell MF, Bornemann R, et al. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2011;8(8):CD004145.
17. D’Onofrio G, O’Connor PG, Pantalon MV, et al. Emergency department—initiated buprenorphine/naltrexone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015;313(16):1636-1644. https://doi.org/10.1001/jama.2015.3474.
18. Florence CS, Zhou C, Luo F, Xu L. The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. Med Care. 2016;54(10):901-906. https://doi.org/10.1097/MLR.0000000000000625.
19. Connock M, Juarez-Garcia A, Jowett S, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess. 2007;11(9):1-171, iii–iv.
20. Baser O, Chalk M, Fiellin DA, et al. Cost and utilization outcomes of opioid-dependence treatments. Am J Manag Care. 2011;17(8):S235-S248.
21. Weiner SG, Price CN, Atalay AJ, et al. A health system–wide initiative to decrease opioid-related morbidity and mortality. Jt Comm J Qual Patient Saf. 2019;45(1):3-13.
22. Substance Abuse and Mental Health Services Administration (SAMHSA). Medications for Opioid Use Disorder for Healthcare and Addiction Professionals, Policymakers, Patients, and Families. The Treatment Improvement Protocol (TIP) 63. U.S. Department of Health and Human Services. https://store.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/PEP20-02-01-006_508.pdf Accessed October 1, 2020.
23. Tompkins DA, Bigelow GE, Harrison JA, Johnson RE, Fudala PJ, Strain EC. Concurrent validation of the clinical opiate withdrawal scale (COWS) and single-item indices against the clinical institute narcotic assessment (CINA) opioid withdrawal instrument. Drug Alcohol Depend. 2009;105(1/2):154-159.
24. Wesson DR, Ling W. The clinical opiate withdrawal scale (COWS). J Psychoactive Drugs. 2003;35(2):253-259.
25. Code of Federal Regulations [Internet]. https://www.ecfr.gov/cgi-bin/retrieveECFR. Retrieved on October 1, 2020.
26. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-174.
27. Cantor AB. Sample-size calculations for Cohen’s kappa. Psychometric Methods. 1996;1(2):150-153. https://doi.org/10.1037/1082-989X. 1.2.150.
28. Corrigan D, Mix RL, Palmer GA, et al. Improving nursing confidence and consistency in assessment of opioid withdrawal: efficacy of simulation and debriefing. J Psychiatr Nurs Ment Health Serv. 2018;56(10):27-35.
29. Nuamah JK, Sasangohar F, Erraguntla M, et al. The past, present and future of opioid withdrawal assessment: a scoping review of scales and technologies. BMC Med Inform Decis Mak. 2019;19:113.
30. Schuckit MA. Treatment of opioid-use disorders. N Engl J Med. 2016;375(4):357-368.
31. Stotts AL, Dodrill CL, Kosten TR. Opioid dependence treatment: options in pharmacotherapy. Expert Opin Pharmacother. 2009;10(11):1727-1740.
32. Fullerton CA, Kim M, Thomas CP, et al. Medication-assisted treatment with methadone: assessing the evidence. Psychiatr Serv. 2014;65(2):146-157.
33. Maglione MA, Raen L, Chen C, et al. Effects of medication assisted treatment (MAT) for opioid use disorder on functional outcomes: a systematic review. J Subst Abus Treat. 2018;89:28-51.
34. Wakeman SE, Larochelle MR, Ameli O, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2):e1920622. https://doi.org/10.1001/jamanetworkopen.2019.20622.
35. Weiner SG, Baker O, Bernson D, Schuur JD. One-year mortality of patients after emergency department treatment for nonfatal opioid overdose. Ann Emerg Med. 2020;5(1):13-17.
36. Canamo LJ, Tronco NB. Clinical opioid withdrawal scale (COWS): implementation and outcomes. Crit Care Nurs Q. 2019;42(3):222-226.

**AUTHOR BIOGRAPHY**

Christian Tomaszewski, MD, MBA, is a Professor of Clinical Emergency Medicine at the University of California, San Diego (UCSD). He works clinically in emergency medicine, medical toxicology, and hyperbaric medicine.

**How to cite this article:** Tomaszewski CA, Quenzer F, Corbett B, et al. Interobserver agreement between emergency clinicians and nurses for Clinical Opiate Withdrawal Scale. JACEP Open. 2021;2:e12462. https://doi.org/10.1002/emp2.12462